Confo Therapeutics has entered into a licensing agreement with Eli Lilly worth up to $630M for the development of its neuropathic pain candidate CFTX-1554.
Target Information
Confo Therapeutics, based in Ghent, Belgium, is a pioneering company specializing in the discovery of medicines that target G-protein coupled receptors (GPCRs). The company is known for its innovative technology that stabilizes functional conformations of GPCRs, enabling the development of conformationally selective chemical or biological ligands. This unique approach allows Confo Therapeutics to build a diverse pipeline of drug candidates aimed at transforming therapeutic outcomes for patients suffering from severe illnesses that currently lack effective treatments.
The company's leading product candidate, CFTX-1554, is a novel inhibitor designed to address neuropathic pain – a challenging condition arising from damage to peripheral nerves. Currently in Phase 1 clinical development, CFTX-1554 represents a non-opioid treatment option, potentially providing relief without the risks of addiction or significant side effects commonly associated with existing therapies.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The pharmaceutical industry in Belgium has demonstrated strong growth, particularly in the life sciences sector, which is characterized by significant investment in research and development. Belgium is home to a vibrant
Similar Deals
Eli Lilly and Company
invested in
Confo Therapeutics
in 2023
in a Other VC deal
Disclosed details
Transaction Size: $630M